Buoyed by news of this week's takeout of Medicines Co., Arrowhead is riding a wave of investor enthusiasm for RNAi therapeutics that has quintupled the company’s share price this year, and has boosted its valuation...

Arrowhead Pharmaceuticals Inc.’s tox blowup in 2016 set back its clinical timelines, but it also prompted the company to bring a more versatile platform online faster than originally planned. Early data from replacement candidates suggest...

Having addressed one of the two big problems of RNAi delivery - getting therapeutic levels of the molecules inside cells - Arrowhead Research Corp. now believes it has solved the second, with a modification to its technology...

Arrowhead Research Corp. (NASDAQ:ARWR) gained $0.68 (12%) to $6.40 on Friday after it selected ARC-HIF2 as its first development candidate using the company's dynamic polyconjugate (DPC) platform for RNAi delivery to tissues outside the liver....